Long-Term Outcomes of Group B Eyes in Patients with Retinoblastoma Treated with Short-Course Chemoreduction: Experience from Children's Hospital Los Angeles/University of Southern California | Zendy

Dagny Zhu | Zendy; Jesse L. Berry | Zendy; Lilangi S. Ediriwickrema | Zendy; Kenneth Wong | Zendy; Thomas C. Lee | Zendy; A. Linn Murphree | Zendy; Jonathan W. Kim | Zendy; Rima Jubran | Zendy

Open Access

Long-Term Outcomes of Group B Eyes in Patients with Retinoblastoma Treated with Short-Course Chemoreduction: Experience from Children's Hospital Los Angeles/University of Southern California

Author(s) -

Dagny Zhu,

Jesse L. Berry,

Lilangi S. Ediriwickrema,

Kenneth Wong,

Thomas C. Lee,

A. Linn Murphree,

Jonathan W. Kim,

Rima Jubran

Publication year - 2015

Publication title -

ocular oncology and pathology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.444

H-Index - 10

eISSN - 2296-4681

pISSN - 2296-4657

DOI - 10.1159/000439593

Subject(s) - medicine , group b , retinoblastoma , surgery , etoposide , enucleation , carboplatin , vincristine , chemotherapy , cyclophosphamide , cisplatin , biochemistry , chemistry , gene

Chemoreduction protocols for retinoblastoma vary widely across institutions. Herein, we compare a 3- versus 6-cycle chemotherapy approach for group B retinoblastoma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research